In vivo CAR-T therapy delivers CAR-encoding transgenes directly to endogenous T cells and reprograms them in situ. The abstract frames this as an alternative to autologous ex vivo CAR-T production.
First-pass extracted concept
in vivo CAR-T therapy
Candidate: concept label2 source documents7 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
in situ programming of CAR-T cells, in vivo CAR cell therapy, in vivo CAR-T
Extracted Explainers
What the tool is doing
Resources required
The approach requires a way to deliver CAR-encoding transgenes to endogenous T cells in vivo. Specific delivery systems are not described in the abstract.
The abstract states that CAR genes must be delivered in vivo using viruses or engineered nanoparticles. No specific vector, nanoparticle composition, or targeting component is given in the abstract.
What problem it solves
It is presented as a way to avoid apheresis, ex vivo cell manufacturing, and lymphodepleting chemotherapy associated with conventional CAR-T therapy. The abstract also emphasizes improved efficiency, lower cost, and broader accessibility.
It is presented as a response to the technical complexity and high production cost of adoptive CAR-T products. The review says this pathway may reduce costs and improve access.
What it does not solve
Alternatives
The abstract contrasts in vivo CAR-T therapy with autologous ex vivo CAR-T cells and conventional CAR-T therapy workflows.
The abstract explicitly contrasts in vivo CAR-T therapy with traditional adoptive CAR-T therapy. It frames adoptive therapy as the established comparator and as a source of enhancement strategies.
Evidence Snippets
In contrast, in vivo CAR-T therapy directly delivers CAR-encoding transgenes to endogenous T cells, reprogramming them in situ.
in vivo CAR-T therapy has been proposed: the in vivo or in situ programming of CAR-T cells to eliminate pathological cells through the delivery of CAR genes in vivo by viruses or engineered nanoparticles
Supporting Sources
Linked Claims
In vivo CAR-T is presented as a more efficient and economical ready-to-use therapeutic paradigm than individualized conventional CAR-T products.
Quoted textsource-backed
Consequently, in vivo CAR-T represents a more efficient and economical paradigm, transforming CAR-T from individualized cellular products towards truly "ready-to-use" therapeutics.
In vivo CAR-T therapy simplifies manufacturing and therapeutic procedures, reduces treatment costs, and improves patient accessibility relative to adoptive CAR-T therapy.
Quoted textsource-backed
This new technology pathway simplifies the manufacturing and therapeutic procedures, reduces treatment costs, and improves patient accessibility
In vivo CAR-T therapy is the in vivo or in situ programming of CAR-T cells to eliminate pathological cells through delivery of CAR genes by viruses or engineered nanoparticles.
Quoted textsource-backed
in vivo CAR-T therapy has been proposed: the in vivo or in situ programming of CAR-T cells to eliminate pathological cells through the delivery of CAR genes in vivo by viruses or engineered nanoparticles
In vivo CAR-T therapy directly delivers CAR-encoding transgenes to endogenous T cells and reprograms them in situ.
Quoted textsource-backed
in vivo CAR-T therapy directly delivers CAR-encoding transgenes to endogenous T cells, reprogramming them in situ
Technical complexity and substantial production costs of adoptive CAR-T therapy products motivate development of in vivo CAR-T therapy.
Quoted textsource-backed
adoptive CAR-T therapy products are difficult to meet the expanding market demand and provide equal access to treatment due to their technical complexity and substantial production costs. These factors drive the development and practice of novel technologies, in this context, in vivo CAR-T therapy has been proposed
In vivo CAR-T therapy has strong potential for clinical application.
Quoted textsource-backed
which has excellent potential for clinical application
In vivo CAR-T therapy obviates the need for apheresis, ex vivo cell manufacturing, and lymphodepleting chemotherapy inherent in conventional CAR-T therapy.
Quoted textsource-backed
This approach obviates the need for apheresis, ex vivo cell manufacturing, and lymphodepleting chemotherapy inherent in conventional CAR-T therapy.